Shengnuo Biotech
SSE · 688117
Market Cap$5.1B
Revenue$801.4M
Listed OnSSE
Ticker688117
CEO / ExecMr. Yongjun Wen
HeadquartersChengdu
MarketMainland China
Websitewww.snbiopharm.com
Overview
ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. The company offers semaglutide, tirzepatide, retatrutide, cagrilintide, lanreotide, bivalirudin, epitifibatide, liraglutide; icatibant, octreotide, teriparatide, ziconotide, ganirelix, linaclotide, abaloparatide, terlipressin acetate; levosimendane, thymosin alpha, enfuvirtide, somatostatin, thymopentin, carbetocin, atosiban acetate, exenatide; and leuprorelin, degarelix, cetr
Data Note
This record combines exchange-directory fields with selected profile enrichment. Treat market data, leadership and financial figures as directional unless verified against company filings, exchange announcements or the issuer's own disclosures.